At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,834 enrolled
Drug / intervention
Losartan 50 mg +1 moredrug
Likely dose
Losartan 50 mg or 150 mg orally dailyAI-extracted
Key inclusion· 2
- ✓Symptomatic heart failure
- ✓Documented intolerance to ACE inhibitor treatment
Key exclusion· 0
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment
In Brief
A Phase 3 clinical trial evaluating Losartan 50 mg and Losartan 150 mg for Heart Failure. Completed, enrolled 3,834 participants.
Detailed Summary
This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2001
First PostedAug 2004
Primary CompletionMar 2009
Study CompletionMay 2009
TodayJul 2026
First PostedAug 27, 2004
Enrollment StartDec 19, 2001
Primary CompletionMar 31, 2009
Study CompletionMay 13, 2009
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 21.8 years ago
Interventions
Losartan 50 mgdrug
50-mg losartan oral tablet
Losartan 150 mgdrug
100-mg losartan oral tablet + 50-mg losartan oral tablet